OMB Individually Reported

Intelligent Document Processing to analyze current import entry documentation for potential discrepancies

Low riskExact public inventory row

Description

The intent is to assist in the process of discrepancy identification between documentation submitted by trade and CBP line data submitted.

Detailed example

List of discrepancies between document data and CBP line level information

AI / analytics pattern

Generative AI: AI that generates new or synthetic content (e.g., images, videos, audio, text, code).

Automation level / stage

a) Pre-deployment – The use case is in a development or acquisition status.

Expected benefit

By streamlining the manual document review process for standard entry documentation from trade, we can significantly reduce the time required for each line review, freeing up substantial analyst capacity to focus on high-risk shipments that pose greater threats to public health and safety. This efficiency improvement enables better resource allocation, reduces processing bottlenecks, and supports faster clearance times for compliant shipments while maintaining robust oversight. The enhanced operational efficiency directly supports FDA's core mission by enabling more targeted, risk-based resource deployment and improving both trade facilitation and import safety program integrity.

Controls / human review

ATO: Not reported; PIA: Not published